本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述 或重大遗漏。 特别提示： 1、本次交易不构成关联交易。 2、本次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组，交易的实 施亦不存在重大法律障碍。 3、根据《深圳证券交易所股票上市规则》相关规定，本次交易在董事会审批权限范围内， 无需提交公司股东大会审议。 证券代码：002262 证券简称：恩华药业 编号：2023-039 江苏恩华药业股份有限公司 关于对控股子公司北京医华增资的公告 一、增资概述 （一）增资事项基本情况 根据控股子公司北京医华移动医疗科技有限公司（以下简称"北京医华"）的经营需要， 增强其资金实力，江苏恩华药业股份有限公司（以下简称 "公司"或"恩华药业"）拟以控 股子公司北京医华截至评估基准日 2023 年 6 月 30 日的评估值为依据，使用公司自有资金 3,000.00 万元人民币对其进行增资并全部计入注册资本。北京医华的其他股东张凤兰、王秀 萍、连欣、李敏均声明放弃其就本次增资可享有的优先认购权。本次增资完成后，北京医华注 册资本由 2,000.00 万元增加至 5,000.00 万元，公司 ...

证券代码：002262 证券简称：恩华药业 公告编号：2023-036 江苏恩华药业股份有限公司 第六届董事会第七次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，对公告的虚假记载、误导性 陈述或重大遗漏负连带责任。 江苏恩华药业股份有限公司（以下简称"公司"）第六届董事会第七次会议于2023年10月 25日在徐州市经济技术开发区龙湖西路31号恩华科技大厦20楼会议室召开，会议通知已于 2023年10月13日以专人送达、传真、电子邮件等方式送达给全体董事、监事和高级管理人员。 本次会议应到董事9名，实到董事9名。公司监事和高级管理人员亦列席本次会议。本次会议 的召集、召开程序符合《中华人民共和国公司法》和《公司章程》的有关规定。 本次会议由董事长孙彭生先生召集并主持，与会董事就本次会议议案进行了审议并以投 票表决的方式，形成了如下决议： 一、会议以9票赞成、0票反对、0票弃权的表决结果审议通过了《公司2023年第三季度报 告》。 董事会及全体董事保证《公司 2023 年第三季度报告》内容的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 《公司2023年 ...

证券代码：002262 证券简称：恩华药业 公告编号：2023-037 江苏恩华药业股份有限公司 江苏恩华药业股份有限公司监事会 2023年10月25日 第六届监事会第七次会议决议公告 1 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏恩华药业股份有限公司（以下简称：公司）监事会于2023年10月13日以电子邮 件或专人送达等方式向全体监事发出召开第六届监事会第七次会议的通知及相关会议资 料。2023年10月25日上午10：00至10：30，第六届监事会第七次会议在徐州市经济技术 开发区龙湖西路31号恩华科技大厦20楼会议室以现场投票表决的方式召开，公司3名监事 全部参加了会议。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》和 本公司章程的规定。 本次会议由监事会主席王丰收先生主持，经与会监事认真审议，并以投票表决方式 一致通过了如下决议： 1、会议以 3 票赞成、0 票反对、0 票弃权的表决结果审议通过了《公司2023年第 三季度报告》。 经审核，监事会认为：董事会编制和审核公司2023年第三季度报告的程序符合法律、 行政法规和中国证监会的有关 ...

北京医华移动医疗科技有限公司 专项审计报告 天衡徐专字(2023)00284 号 天衡会计师事务所(特殊普通合伙)徐州分所 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）" 报告编码: ▽天衡会计师事务所(特殊普通合伙 徐州分所 北京医华移动医疗科技有限公司专项审计报告 批准的项目外，凭营业执照依法自主开展经营活动）许可项目：基础电信业务; 互联网信息服务；在线数据处理与交易处理业务（经营类电子商务);第二类增 值电信业务。(依法须经批准的项目,经相关部门批准后方可开展经营活动，具 体经营项目以相关部门批准文件或许可证件为准）(不得从事国家和本市产业政 策禁止和限制类项目的经营活动)。 二、审计情况 天衡徐专字(2023)00284 号 专项审计报告 江苏恩华药业股份有限公司: 我们接受委托，对北京医华移动医疗科技有限公司 (以下简称"北京医华移 动"、"该公司"）截至 2023 年 6 月 30 日止的财务状况进行了专项审计。北京医 华移动的责任是提供审计所需的真实、合法、完整的会计资料及其他有关资料, 我们的责任是在实施审计工作的基础上对上述审计事项 ...

| 股东名称 | 减持方式 | 减持均价（元） | 减持股数（万股） | 占公司总股本的比例（%） | | --- | --- | --- | --- | --- | | 恩华投资 | 大宗交易 | 24.84 | 1,403.00 | 1.39% | | | 合计 | | 1,403.00 | 1.39% | 二、股东减持股份比例超过 1%的具体情况 证券代码：002262 证券简称：恩华药业 公告编号：2023-035 江苏恩华药业股份有限公司 关于持股 5%以上股东通过大宗交易方式减持公司股份超过 1%及承诺 未来 6 个月内不再减持公司股份的公告 持股 5%以上股东徐州恩华投资有限公司保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 江苏恩华药业股份有限公司（以下简称"公司"）近日收到持股 5%以上股东徐州恩华投资 有限公司（以下简称"恩华投资"）出具的《关于通过大宗交易方式减持江苏恩华药业股份有限 公司部分股份的告知及承诺函》，恩华投资因其自身资金需要，近期通过深圳证券交易所大宗 交易系统减持其持有 ...

Industry Challenges and Risks - The company reported a significant impact from industry policy changes, including stricter drug approval and quality regulations, which pose risks to future development [2]. - Environmental risks are highlighted due to potential pollution from production processes, which could affect the company's operations and compliance with national regulations [3]. - The company faces challenges in talent acquisition, particularly in management and specialized fields, which may hinder strategic execution and growth [3]. - The company is aware of the potential for extended research timelines and failures in drug development due to increasing regulatory scrutiny [3]. - The company faces risks related to industry policy changes, quality control, and innovation in drug development, which could impact operational performance [69]. Financial Performance - The company's operating revenue for the first half of 2023 was ¥2,400,328,791.85, representing a 19.95% increase compared to ¥2,001,098,966.90 in the same period last year [14]. - The net profit attributable to shareholders was ¥544,703,014.00, up 21.72% from ¥447,503,891.51 in the previous year [14]. - The basic earnings per share increased to ¥0.54, reflecting a growth of 22.73% compared to ¥0.44 in the same period last year [14]. - The total assets at the end of the reporting period were ¥6,830,642,973.77, a 5.38% increase from ¥6,481,745,574.76 at the end of the previous year [14]. - The net assets attributable to shareholders increased to ¥5,965,434,019.97, marking a 6.10% rise from ¥5,622,248,624.37 at the end of the previous year [14]. - The company reported a net cash flow from operating activities of ¥445,744,450.97, which is a 12.72% increase from ¥395,457,761.66 in the same period last year [14]. Research and Development - The company plans to invest heavily in new drug research and development, with a focus on innovative drugs and consistency evaluations for generic drugs, acknowledging the high costs and long timelines involved [3]. - The company increased R&D investment to approximately 282 million CNY, a 35.09% increase year-over-year, focusing on innovative drug development and key generic drug projects [21]. - There are over 80 ongoing research projects, with 25 innovative drug projects currently in development, including 1 in Phase II and 6 in Phase I clinical trials [21]. - The company has received approval for two consistency evaluation projects in the first half of 2023, including the hydrochloride buprenorphine injection and the hydrochloride butyrophenone injection [21]. - The company has applied for 56 invention patents and received 8 authorized invention patents during the reporting period [21]. Environmental Management - The company invested approximately CNY 15.22 million in environmental protection and governance, focusing on green production initiatives [46]. - The company has established a comprehensive environmental management system to meet national and local environmental laws and standards [74]. - The company has a valid pollution discharge permit effective until March 20, 2028, following recent approvals [76]. - The company has reported no exceedances in pollution discharge limits according to the latest assessments [76]. - The company has reduced solvent usage significantly by introducing green production processes, leading to an estimated 90% reduction in waste generation [83]. Market Strategy and Expansion - The company aims to enhance its market position in the central nervous system drug sector through specialized marketing strategies and product differentiation [48]. - The company’s sales strategy includes leveraging multiple online platforms such as Tmall, JD.com, Meituan, and Pinduoduo for e-commerce growth [22]. - The company is actively expanding its digital healthcare ecosystem around CNS drugs, including precision and smart healthcare initiatives [22]. - The company has deepened its market penetration in county-level and private hospitals, ensuring fast growth for non-bid products [28]. - The company is focusing on digital chronic disease management, particularly in mental health, to improve patient care and management [42]. Corporate Governance and Accountability - The management team has confirmed the accuracy and completeness of the financial report, ensuring accountability for the information presented [2]. - The company will not distribute cash dividends or issue bonus shares for the year 2023, indicating a focus on reinvestment [4]. - The company has no current employee stock ownership plans or other incentive measures in place [73]. - The company has a three-year action agreement in place among its actual controllers, effective since April 15, 2021 [100]. - The company has not conducted any repurchase transactions among the top 10 shareholders during the reporting period [101]. Future Outlook - The company aims to achieve its operational goals for 2023 despite the outlined risks, demonstrating a commitment to proactive risk management [4]. - The company plans to continue enhancing its mental health service system and invest in smart technology research and development [54]. - The company is actively preparing for an IPO while conducting D-round financing for Jiangsu Haoxin Qing [42]. - The company is focusing on research and development of new technologies to drive future growth and innovation in its product offerings [126]. - The company aims to enhance its market presence through potential mergers and acquisitions, aligning with its long-term strategic goals [126].

Financial Performance - The company's revenue for Q1 2023 was CNY 1,178,806,488.43, representing an increase of 18.76% compared to CNY 992,593,188.54 in the same period last year[3] - Net profit attributable to shareholders was CNY 227,429,413.46, up 20.53% from CNY 188,688,696.04 year-on-year[3] - The net cash flow from operating activities reached CNY 364,395,839.44, reflecting a growth of 27.34% compared to CNY 286,170,933.07 in the previous year[3] - Total operating revenue for Q1 2023 reached CNY 1,178,806,488.43, an increase of 18.7% compared to CNY 992,593,188.54 in Q1 2022[18] - Operating profit for the quarter was CNY 261,579,559.01, representing a 24.7% increase from CNY 209,692,665.09 in Q1 2022[19] - Net profit attributable to the parent company was CNY 227,429,413.46, up 20.6% from CNY 188,688,696.04 in the same period last year[19] - Basic earnings per share for Q1 2023 is CNY 0.484, up 10% from CNY 0.44 year-on-year[14] - Earnings per share for the quarter were CNY 0.23, up from CNY 0.19 in the same period last year[20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,815,268,549.17, an increase of 5.15% from CNY 6,481,745,574.76 at the end of the previous year[3] - The total assets as of March 31, 2023, amount to CNY 6,815,268,549.17, an increase from CNY 6,481,745,574.76 at the beginning of the year[16] - The total liabilities as of March 31, 2023, are CNY 906,092,526.39, compared to CNY 793,943,159.84 at the beginning of the year[16] - Total liabilities increased to CNY 1,005,339,007.70, up from CNY 896,989,429.48, indicating a rise of 12.1%[19] - The company's total equity attributable to shareholders reached CNY 5,849,678,037.83, compared to CNY 5,622,248,624.37, marking an increase of 4.0%[19] Cash Flow - The company reported a decrease of 107.70% in net increase in cash and cash equivalents, influenced by cash flows from operating, investing, and financing activities[8] - Cash and cash equivalents at the end of Q1 2023 are CNY 1,519,601,953.76, slightly down from CNY 1,532,214,418.85 at the beginning of the year[15] - Cash inflow from financing activities was 25,000,000.00 CNY, unchanged from the previous year[22] - Cash outflow for financing activities was 15,969,215.29 CNY, slightly down from 16,437,185.78 CNY in the previous year[22] - The company reported a decrease in cash and cash equivalents by 14,166,509.61 CNY during the quarter[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,244, with the largest shareholder holding 35.15% of the shares[9] - The company has a significant shareholder structure, with the top 10 shareholders holding a combined 55.58% of the shares[11] Investment Income - Investment income from financial products was CNY 11,360,194.34, indicating a significant increase of 475.22% year-on-year due to higher returns from financial investments[5][7] - The company recorded investment income of CNY 15,867,492.31, significantly higher than CNY 2,758,525.71 in Q1 2022[19] Tax and Expenses - The company experienced a 55.13% increase in income tax expenses, attributed to higher total profits and deferred tax assets[7] - Research and development expenses amounted to CNY 109,676,566.12, an increase of 8.2% from CNY 100,832,530.58 in Q1 2022[18] Future Outlook - The company expects a positive performance outlook for the first half of 2023, with an upward trend in operating results[13] Other Information - The company did not undergo an audit for the first quarter report[23] - The cash flow from operating activities was not detailed in the provided documents[22]

江苏恩华药业股份有限公司投资者关系活动记录表 编号：2023-001 | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | 活动参与人员 | 1、公司参与人员：公司总经理孙家权、独立董事陈国祥、董事会 | | | 秘书段保州、财务负责人李岗生。 | | | 2、参与的投资者详见附件。 | | 时间 | 2023 年 3 月 28 日下午 15:00-17：00 | | 地点 | 全景网"投资者关系互动平台" （https://ir.p5w.net） | | 形式 | 采用网络远程的方式 | | 交流内容及具体问答记 | 详见附件。 | | 录 | | | 关于本次活动是否涉及 | 本次活动未涉及应披露重大信息。 | | 应披露重大信息的说明 | | | 活动过程中所使用的演 | 无。 | | 示文稿、提供的文档等 | | | 附件（如有，可作为附 | | | 件） | | 附件： 江苏恩华药业股份有限公司 2022 年度业绩说 ...

Financial Performance - The company's operating revenue for 2022 was ¥4,298,513,062.14, representing a year-on-year increase of 9.22% from ¥3,935,664,219.52 in 2021[13]. - The net profit attributable to shareholders for 2022 was ¥900,926,029.55, which is a 12.93% increase compared to ¥797,777,327.57 in 2021[13]. - The basic earnings per share for 2022 was ¥0.89, up 12.66% from ¥0.79 in 2021[13]. - The total assets at the end of 2022 amounted to ¥6,481,745,574.76, reflecting a 13.77% increase from ¥5,697,186,706.05 at the end of 2021[13]. - The net assets attributable to shareholders at the end of 2022 were ¥5,622,248,624.37, which is a 14.26% increase from ¥4,920,688,031.43 at the end of 2021[13]. - In Q4 2022, the operating revenue reached ¥1,178,387,350.86, with a net profit attributable to shareholders of ¥159,051,214.46[16]. - The company reported a cash flow from operating activities of ¥861,023,149.69 for the year 2022, which is a 22.81% increase from ¥701,117,596.67 in 2021[13]. - The company recognized government subsidies amounting to ¥46,912,734.05 in 2022, compared to ¥32,743,590.42 in 2021[17]. - The weighted average return on equity for 2022 was 17.20%, slightly down from 17.69% in 2021[13]. - The company reported a total of ¥28,166,708.35 in non-recurring gains and losses for 2022[17]. Dividend Distribution - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares to all shareholders, based on a total of 1,007,588,092 shares[2]. - The proposed cash dividend for 2022 is ¥2.00 per 10 shares, totaling ¥201,517,618.40, with no stock dividends or capital reserve transfers[133]. - The cumulative cash dividend amount from 2019 to 2021 was approximately ¥604.19 million, accounting for 82.77% of the average annual net profit during the same period[153]. - After the dividend distribution, the retained undistributed profit will be ¥3,776,835,195.20, to be carried forward for future distribution[133]. Market and Industry Trends - The pharmaceutical industry in China is experiencing significant growth, with healthcare expenditure as a percentage of GDP reaching 4.83% in 2022, indicating a rising demand for medical services[21]. - Chronic disease prevalence in China has reached 23%, with chronic diseases accounting for 86% of total deaths, leading to increased long-term medication and healthcare costs[21]. - The central nervous system (CNS) drug market in China is still in its early stages, with only 3% of the global CNS drug consumption, compared to 49% in the US and 26% in Europe[23]. - The aging population and rising health awareness among the public are expected to drive further growth in the pharmaceutical sector, presenting significant opportunities for companies like Jiangsu Enhua[22]. - The ongoing healthcare reforms and policies, such as centralized procurement, are pushing pharmaceutical companies to innovate and improve their R&D capabilities[21]. Research and Development - The company has a robust product pipeline with 22 innovative drug projects and 38 generic drug projects currently under development, alongside 15 projects undergoing consistency evaluation[23]. - The company increased R&D investment to CNY 495,383,504.42, a growth of 23.10% compared to the previous year, with over 70 ongoing research projects[30]. - There are currently 22 innovative drug projects under development, including 1 in Phase II clinical trials and 4 in Phase I clinical trials, with 5 projects expected to submit clinical applications in 2023[30]. - The company has launched 38 generic drug projects, with 2 generic drug production approvals obtained during the reporting period[30]. - The company has applied for 127 invention patents and received 44 authorized invention patents during the reporting period[30]. Corporate Governance - The company reported a commitment to improving corporate governance, aligning with regulations from the China Securities Regulatory Commission and the Shenzhen Stock Exchange, enhancing internal control systems[97]. - The board of directors consists of four independent directors, exceeding one-third of the total board members, ensuring compliance with governance standards[98]. - The company has established a mechanism to prevent major shareholders from occupying company funds, safeguarding the interests of minority shareholders[97]. - The company emphasizes transparent communication with investors, implementing various channels for interaction, including online platforms and direct communication[99]. - The company has a comprehensive human resources management system that includes detailed regulations on recruitment, training, compensation, and performance evaluation[154]. Environmental Responsibility - The company strictly adheres to environmental protection laws and regulations, ensuring wastewater and air emissions meet national standards[143]. - The company invested approximately CNY 15.22 million in environmental governance and protection, including the purchase of environmental protection equipment and facility upgrades[151]. - The company implemented a wastewater treatment system with a capacity of 800 tons per day at the Jinshanqiao plant, ensuring that treated wastewater meets discharge standards[146]. - The company achieved over 95% efficiency in VOC treatment after upgrading its exhaust gas treatment systems, with an investment of CNY 3 million in 2022[147]. - The company has not faced any administrative penalties related to environmental issues in 2022[152]. Social Responsibility - The company actively participates in charitable activities, contributing medicines and funds to local poverty alleviation efforts, enhancing its social responsibility image[99]. - The company has established the "Enhua Caring Fund," which has donated a total of 807,800 yuan to assist socially disadvantaged families over the past seven years[159]. - The company collaborates with Nanjing Medical University to provide 60,000 yuan in scholarships annually to outstanding students in the field of psychiatry[159]. - The company has committed 480,000 yuan to support rural revitalization efforts, directly benefiting local communities[160]. - The company has been fulfilling its social responsibilities by supporting education, culture, science, and health initiatives in local areas[159]. Future Outlook - The company aims for approximately 15% growth in business revenue, total profit, and net profit in 2023 compared to the audited data of 2022[86]. - The company plans to advance 6 innovative drug clinical trials in 2023 and aims to establish 3-5 new innovative drug projects, with a goal of submitting 5 innovative drug applications for clinical trials[86]. - The company is focusing on high-barrier generic drugs and has 4 projects undergoing consistency evaluation, with 3 expected to be approved in 2023[87]. - The company is enhancing its marketing strategies to strengthen new product market access and aims to maintain its leading position in the central nervous system drug sector[88]. - The company is committed to optimizing production management and cost control, with a focus on improving product quality and reducing complaints[87].

江苏恩华药业股份有限公司 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002262 证券简称：恩华药业 公告编号：2023-012 江苏恩华药业股份有限公司（以下简称"公司"）定于2023年3月28日（星期二）15:00- 17:00在全景网举办2022年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行， 投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 公司出席本次说明会的人员有：公司总经理孙家权、董事会秘书段保州、财务负责人李 岗生、独立董事陈国祥。 问题征集专题页面二维码 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前向投资者公 开征集问题，广泛听取投资者的意见和建议。投资者可于2023年3月27日（星期一）17：00前 访问https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面。公司将在2022年度业 绩说明会上，对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上说明会 ...